Immunization and equity in the regional initiative of the mesoamerican health initiative;Inmunizaciones y equidad en el polan regional del Sistema Mesoamericano de salud Pública

Salud Publica de Mexico

Volumn 53, Issue SUPPL. 3, 2011, Pages

  Franco Paredes, Carlos ^a,d   Hernández Ramos, Isabel ^b   Santos Preciado, José Ignacio ^a,c   Santos Preciado, José I ^d   Hernández Flores, Isabel ^d   Veras, Miriam ^d   Angel Nakamura, M ^d   Fernández, Sonia ^d   Monterroso, Edgar ^d   Asturias, Edwin ^d   Pavia Ruz, Noris ^d   Wong Chew, Rosa María ^d   Valdespino, José Luis ^d   de León, Samuel Ponce ^d   Guerrero, Gladys ^d   Suárez Castañeda, Eduardo ^d   Villatoro de Mtz, Nora María ^d   Berenice Molina, Ida ^d   Reyes, Martha ^d   Barrera Arreola, Lesbia Lisette ^d   Richardson, Vesta ^d   López Ortiz, Araceli ^d   Arroba, Roberto ^d   Largaespada, Natalia ^d   Wright, Eufemia ^d   Valencia, Atanacio ^d   Zeuli, Julia ^d   more..

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF GUANAJUATO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d NONE

Author keywords

Immunization; Latin America; Poverty; Public policies; Universal coverage

Indexed keywords

EID: 84858645404     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Gwatkin DS. How much would poor people gain from faster progress towards the Millennium Development Goals for health? Lancet 2005; 365 (9461): 813-817.
2. Gwatkin DS. Ensuring that the poor share fully in the benefits of results-based financing program in health. Results for Development Institute and Johns Hopkins Bloomberg School of Public Health. Washington: The World Bank, 2009.
3. World Health Organization. Maximizing Positive Synergies Collaborative Group. An Assessment of interactions between Global Health Initiatives and Country Health Systems. Lancet 2009; 373 (9681): 2137-2169.
4. Editorial The Lancet. Venice Statement: Global Health Initiatives and Health Systems. Lancet 2009; 347 (9683): 10-12.
5. Franco-Paredes C, Jones D, Rodriguez-Morales AJ, Santos-Preciado JI. Improving the Health of Neglected Populations in Latin America. BMC Public Health 2007;7.
6. Barros AJD, Victora CG, Cesar JA. Brazil: Are health and nutrition programs reaching the neediest? In: Reaching the poor with health, nutrition and population services. Gwatkin Dr. Wagstaff A, Yazbeck AS. Washington: World Bank, 2005:281-306.
7. Instituto Nacional de Salud Pública. Encuesta Nacional de Cobertura Rápida 2008. Resumen ejecutivo sobre el componente de vacunación en niños menores de 2 años.
8. Sclar ED, Garau P, Carolini G. The 21st century health challenge of slums and cities. Lancet 2005; 365(9462): 901-903.
9. Victora CG, Wagstaff A, Schellenberg JA, Gwatkin D, Claeson M, Habicht JP. Applying an equity lens to child health and mortality: more of the same is not enough. Lancet 2003; 362(9379): 233-241.
10. Marmot M. Health in an unequal world: social circumstances, biology and disease. Clin Med 2006;6(6):559-572.
11. UNDP. UNDP 2009 Human development report. Overcoming barriers: Human mobility and development. [Consultado 2011, Febrero 23]; Disponible: http://hdr.undp.org/en/reports/global/hdr2009.
12. The World Health Organization. Country Cooperation Strategy Briefs. 2009.
13. DeRoeck D, Bawazir SA, Carrasco P. Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program. Int J Health Plann Manage 2006; 21(1): 23-43.
14. World Bank. Comprehensive Development Framework [Consultado Febrero 23, 2011]; Disponible:http://web.worldbank.org/WBSITE/EXTERNAL/PROJECTS/0,contentMDK:20120725~menuPK:41393~pagePK:41367~piPK:51533~theSitePK:40941,00.html
15. World Bank. Cooperation between Mexico and the World Bank. [Consultado 2011, Febrero 23, 2011]; Disponible: http://web.worldbank.org/WBSITE/EXTERNAL/BANCOMUNDIAL/EXTSPPAISES/LACINSPANISHEXT/MEXICOINSPANISHEXT/0.contentMDK:21028834~pagePK:141137~piPK:141127~theSitePK:500870,00.html
16. Anta R, El-Wahab S, Giuffrida A. Mobile health: the potential of mobile telephony to bring health care to the majority. Washington DC: Inter-American Development Bank, 2009.
17. Inter-American Development Bank. Mobile Citizen. Empowering people through mobile services. Washington DC: Inter-American Development Bank. Call for Problems. Inter-American Development Bank, 2009.
18. Global Alliance for Vaccine Initiative (GAVI). Experiences of the GAVI Alliance health system strengthening investment. 2007. [Consultado 2011, Febrero 23]; Disponible: http://www.gavialliance.org.
19. GAVI Secretariat. GAVI Alliance Strategy (2007-10). [Consultado 2011, Febrero 23]; Disponible: http:www.gavialliance.org.
20. Global Alliance for Vaccine Initiative (GAVI). Support for health system strengthening. Good examples from country proposals. [Consultado 2011, Febrero 23]; Disponible: http://www.gavialliance.org/resources/GAVI_HSS_proposals_good_examples_Oct_2008.pdf.
21. Commission on the Future of Vaccines in Latin America. Strengthening vaccination policies in Latin America. Instituto CARSO de la Salud. Fundacion Carlos Slim. 2008.
22. Van Domelen J. Reaching the Poor and Vulnerable: Targeting Strategies for Social Funds and other Community-Driven Programs. In: Network HD. Washington DC: World Bank, 2007:1-52.
23. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Roses-Periago M. The Neglected Tropical Diseases of Latin America and the Caribbean: Estimated Disease Burden and Distribution and a Roadmap for Control and Elimination. PLoS Negl Trop Dis 2008; 2: e300.
24. Hotez PJ, Molyneux DH, Fenwick A, Ottessen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases. PloS Med 2006; 3(5): e102.
25. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005; 2(11): e336.
26. Young MW. The Catalytic Initiative to save a Million lives: overview and latest update of the Catalytic Initiative. UNICEF. Global Immunization Meeting, New York. February 2009. [Consultado 2011, Febrero 23]; Disponible: www.who.int/immunization/newsroom/190209_M_Young.pdf.
27. Barton JH. Financing of vaccines. Lancet 2000; 355, 1269-1270.
28. Bloom D, Canning D, Weston M. The value of vaccination. World Economics 2005; 6(3):15-30.
29. Chokshi D, Kesselheim AS. Rethinking global access to vaccines. BMJ 2008;336:750-753.
30. Ehreth J. The Value of vaccination: a global perspective. Vaccine 2003;21(27-30):4105-17.
31. Gauri V, Khalegian P. Immunization in developing countries: its political and organizational determinants. Policy Research Working Paper Series 2002; 2769. Washington DC: World Bank, 2002.
32. Moloney A. Latin America faces hurdles in health research. Lancet 2009; 374 (9695): 1053-1054.
33. Zachariah R, Harries AD, Ishikawa N, Rieder HL, Bissell K, Laserson K, et al. Operational Research in low income countries: what, why, and how? Lancet Infect Dis 2009; 9: 711-717.
34. Caceres CF, Mendoza W. Globalized research and "national science". Am J Public Health 2009; 99: 1792-1798.
35. Sivasankaran S, Manickam P, Ramakrishnan R, Hutin Y, Gupte MD. Centers for Disease Control and Prevention (CDC). Estimation of measles vaccination coverage using the Lot Quality Assurance Sampling (LQAS) method-Tamilnadu, India, 2002-2003. MMWR Morb Mortal Wkly Rep 2006;55 Suppl 1:16-9.
36. Victora CG, Vaughan JP, Barros FC, Silva AC, Tomasi E. Explaining trends in inequalities: Evidence from Brazilian Child Health Studies. Lancet 2000;356:1093-1098.
37. Dietz V, Venczel L, Izurieta H, Stroh G, Zeli ER, Monterroso E, et al. Assessing and monitoring vaccination coverage levels: lessons from the Americas. Pan Am J Public Health 2004;16(6):432-442.
38. Fairbrother G, Freed G, Thompson J. Measuring immunization coverage. American Journal of Preventive Medicine 2000; 19(S3):78-88.
39. Alberti KP, Guthmann JP, Fermon F, Nargaye KD, Grais RF. Use of lot quality assurance sampling (LQAS) to estimate vaccination coverage helps guide future vaccination efforts. Trans R Soc Trop Med Hyg 2008; 102: 251-254.
40. Hedth BL, Olives C, Pagano M, Valadez JJ. Large country lot quality assurance sampling. A New Method for Rapid Monitoring and Evaluation of Health, Nutrition and Population Programs at Sub-National Levels. Health, Nutrition and Population. Washington DC: World Bank, 2008.
41. Tawfik Y, Houque S, Siddiqi M. Using lot quality assurance sampling to improve immunization coverage in Bangladesh. Bulletin of the World Health Organization 2001; 79:501-505.
42. Cakir B. Lot Quality Survey: an appealing method for rapid evaluation for rapid evaluation of vaccine coverage in developing countriesexperience in Turkey. BMC Public Health 2008; 8:240.
43. Lozano R, Soliz P, Gakidou E, Abbott-Klafter J, Feehan DM, Vidal C, et al. Benchmarking of performance of Mexican states with effective coverage. The Lancet 2006;368:1729-1741.
44. Shengelia B, Tandon A, Adams OB, Murray CJL. Access, utilization, quality and effective coverage: an integrated conceptual framework and measurement strategy. Social Sci & Med 2005;61:97-109.
45. Zakus JD, Lysack CL. Revisiting community participation. Health Policy Plan 1998;13(1):1-12.
46. Morgan LM. Community participation in health: perpetual allure, persistent challenge. Health Policy Plan 2001;16(3):221-230.
47. Montenegro RA, Stephens C. Indigenous health in Latin America and the Caribbean. Lancet 2006;367:1859-1869.
48. Gwatkin D. Overcoming the inverse care law. Designing health programs to serve disadvantaged populations groups in developing countries. Washington DC: World Bank, 2001.
49. Green L, Mercer SL. Can public health researchers and agencies reconcile the push from funding bodies and the pull from communities? Am J Public Health 2001;91(12):1926-1929.
50. Rynman TK, Dietz V, Cairns KL. Too little but not too late: results of a literature review to improve routine immunization programs in developing countries. BMC Health Services Research 2008;8:134.
51. King M, Smith A, Gracey M. Indigenous health part 2: the underlying causes of the health gap. Lancet 2009;374:76-85.
52. Silfverdal SA, Berg S, Hemlin C, Jokinen I. The cost-burden of paediatric pneumococcal disease in Sweden and the potential costeffectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 2009;27:1601-1608.
53. Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Costeffectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States. Vaccine 2009;5;27(47):6483-6494.
54. Claes C, Reinert RR, von der Schulenburg JM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 2009;10:25-38.
55. Sinha A, Constenla D, Valencia JE, O'Loughlin R, Gomez E, de la Hoz F, et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica 2008;24:304-313.
56. Constenla DO. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publica 2008;24:101-112.
57. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Costeffectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008;9:7-15.
58. Bergman A, Hjelmgren J, Ortqvist A, Wisloff T, Kristiansen IS, Hogberg LD, et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis 2008;40:721-729.
59. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369:389-396.
60. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Costeffectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006;25:494-501.
61. Wisloff T, Abrahamsen TG, Bergsaker MA, Lovoll O, Moller P, Pedersen MK, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006;24:5690-5699.
62. Marchetti M, Colombo GL. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 2005;23:4565-4566.
63. Navas E, Salleras L, Gisbert R, Dominguez A, Timoner E, Ibanez D, et al. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 2005;23:2342-2348.
64. Salo H, Sintonen H, Nuorti JP, Linna M, Nohynek H, Verho J, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis 2005;37:821-832.
65. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004;22:4203-4214.
66. Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, et al. Pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 2004;7:36-51.
67. Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004;22:1138-1149.
68. Bos JM, Rumke H, Welte R, Postma MJ. Epidemiologic impact and costeffectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 2003;25:2614-2630.
69. Claes C, Graf von der Schulenburg JM. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 2003;21:587-600
70. De Wals P, Petit G, Erickson LJ, Guay M, Tam T, Law B, et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 2003;21:3757-3764.
71. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 2003;21:3273-3281.
72. Lebel MH, Kellner JD, Ford-Jones EL, Hvidsten K, Wang EC, Ciuryla V, et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003;36:259-268.
73. McIntosh ED, Conway P, Willingham J, Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential costeffectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 2003;21:2564-2572.
74. Moore D, Bigham M, Patrick D. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can Commun Dis Rep 2003;29:97-104.
75. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000;283:1460-1468.
76. Constenla D, Velazquez FR, Rheingans RD, Antil L, Cervantes Y. Economic impact of a rotavirus vaccination program in Mexico. Revista Panamericana de Salud Publica 2009;25:481-490.
77. Panatto D, Amicizia D, Ansaldi F, Marocco A, Marchetti F, Bamfi F, et al. Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy). Vaccine 2009;27:3450-3453.
78. Martin A, Batty A, Roberts JA, Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009;27:4520-4528.
79. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009;9:29.
80. Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008;26:388-396.
81. Goossens LM, Standaert B, Hartwig N, Hovels AM, Al MJ. The costutility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008;26:1118-1127.
82. de Soarez PC, Valentim J, Sartori AM, Novaes HM. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008;23:221-230.
83. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007;21:205-216.
84. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007;25:373-380.
85. Constenla D, O'Ryan M, Navarrete MS, Antil L, Rheingans RD. Potential cost effectiveness of a rotavirus vaccine in Chile. Rev Med Chil 2006;134:679-688.
86. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005;192 Suppl 1:S133-S537.
87. Shim E, Galvani AP. Impact of transmission dynamics on the costeffectiveness of rotavirus vaccination. Vaccine 2009;27:4025-4030.
88. Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R. Costeffectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis 2008;8:103.
89. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007;119:684-697.
90. Wu CL, Yang YC, Huang LM, Chen KT. Cost-effectiveness of childhood rotavirus vaccination in Taiwan. Vaccine 2009;27:1492-1499.
91. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2009;29:33-50.
92. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007;25:3971-3979.
93. Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR. The costeffectiveness of rotavirus vaccination in Australia. Vaccine 2007;25: 8851-8860.
94. Gwatkin DR, Wagstaff A, Yazbeck A (eds). Reaching the poor with health, nutrition, and population services: what works, what doesn't, and why. Washington DC, 2005. The World Bank.
95. Gwatkin DR, Bhulya A, Victoria CG. Making health systems more equitable. Lancet 2004;364:1273-1280.
96. U.S. Coalition for Child Survival. [Consultado 2011, Febrero 23]; Disponible: http://www.child-survival.org.
97. Fields R, Steinglass R. Immunizing the World's Children: Strong and Steady Wins the Race. Field Note. Global Health Council. [Consultado 2011, Febrero 23]; Disponible: http://www.globalhealth.org/reports/text.php3?id=188.
98. Fernald LCH, Gertler PJ, Neufeld LM. Role of cash in conditional cash transfer programmes for child health, growth, and development: an analysis of Mexico's Oportunidades. Lancet 2008;371:828-837.
99. Shimp L. What is Reaching Every District (RED) in immunization?: A brief overview. The Communication Initiative Network. [Consultado 2011, febrero 23]; Disponible: http://comminit.com. Accessed: October 18, 2009.
100. Marmot M. Health in an unequal world. Lancet 2006;368:2081-2094.
101. Friel S, Bell R, Marmont, M et al. Call all Don Quixotes and Sancho Panzas: achieving the dream of global health equity through practical action on the social determinants of health. Global Health Promotion 2009;Suppl (1);9-13.
102. Ronveaux O, Rickert D, Hadler S, Groom H, Lloyd J, Bchir A, et al. The immunization data quality audit: verifying the quality and consistency of immunization monitoring systems. Bull World Health Org 2005;83:503-510.
103. Djibuti M, Gotsadze G, Zoidze A, Mataradze G, Esmail L, Kohler JC. The role of supportive supervision on immunization program outcome - a randomized field trial from Georgia. BMC International Health and human Rights 2009; 9 (suppl 1):S11.
104. King M, Gracey M. Indigenous health part 1: determinants and disease patterns. Lancet 2009;374:65-75.
105. World Health Organization. The right to health - the fact sheet. Geneva, Switzerland: WHO, 2007.
106. Piller C, Smith C. A Times Investigation: Unintended victims of Gates Foundation Generosity. Los Angeles Times, December 16, 2007.
107. World Health Organization. Everybody's business - Strengthening Health Systems to Improve Outcomes: WHO's framework for action. Geneva: WHO, 2007.
108. Frenk J. Reinventing primary health care: the need for systems integration. Lancet 2009;374(9684):170-173.
109. Editorial The Lancet. Who runs global health? Lancet 2009; 373: 2083.
110. de Waal A. Famine crimes: politics & the disaster relief industry in Africa. Bloomington, Indiana University Press, 1997.
111. WHO, UNICEF, World Bank. State of the World's Immunization and Vaccines. 3rd Edition, Geneva, Switzerland: WHO, 2009.